Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Clinical trial NCT02650648 · COMPLETED
Trial details
- NCT number
- NCT02650648
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-05
- Primary completion
- 2025-07-28
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.